Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-11-08

Study Completion Date

2016-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized phase I trial studies the side effects and best dose of nanosomal docetaxel lipid suspension in treating patients with advanced solid tumors. Drugs used in chemotherapy, such as nanosomal docetaxel lipid suspension, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies

NCT01103791

Advanced Solid Malignancies

COMPLETED PHASE1

A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors

NCT03934359

Advanced Solid Tumors

COMPLETED PHASE1

PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic

NCT01540253

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors

NCT00003430

Head and Neck Cancer Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors

NCT01907685

Advanced Neoplastic Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To assess the pharmacokinetics profile of nanosomal docetaxel lipid suspension (NDLS) in patients with advanced solid tumors.

SECONDARY OBJECTIVES:

I. To assess the safety and toxicity of NDLS in patients with advanced solid tumors.

OUTLINE: Patients are randomized to 1 of 4 treatment arms.

ARM I: Patients receive lowest dose nanosomal docetaxel lipid suspension intravenously (IV) over 1 hour.

ARM II: Patients receive low dose nanosomal docetaxel lipid suspension IV over 1 hour.

ARM III: Patients receive high dose nanosomal docetaxel lipid suspension IV over 1 hour.

ARM IV: Patients receive highest dose nanosomal docetaxel lipid suspension IV over 1 hour. In all arms, treatment may repeat every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Unspecified Adult Solid Tumor, Protocol Specific

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (lowest dose NDLS)

Patients receive lowest dose nanosomal docetaxel lipid suspension IV over 1 hour.

Group Type EXPERIMENTAL

nanosomal docetaxel lipid suspension

Intervention Type DRUG

Given IV

pharmacological study

Intervention Type OTHER

Correlative studies

Arm II (low dose NDLS)

Patients receive low dose nanosomal docetaxel lipid suspension IV over 1 hour.

Group Type EXPERIMENTAL

nanosomal docetaxel lipid suspension

Intervention Type DRUG

Given IV

pharmacological study

Intervention Type OTHER

Correlative studies

Arm III (high dose NDLS)

Patients receive high dose nanosomal docetaxel lipid suspension IV over 1 hour.

Group Type EXPERIMENTAL

nanosomal docetaxel lipid suspension

Intervention Type DRUG

Given IV

pharmacological study

Intervention Type OTHER

Correlative studies

Arm IV (highest dose NDLS)

Patients receive highest dose nanosomal docetaxel lipid suspension IV over 1 hour.

Group Type EXPERIMENTAL

nanosomal docetaxel lipid suspension

Intervention Type DRUG

Given IV

pharmacological study

Intervention Type OTHER

Correlative studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nanosomal docetaxel lipid suspension

Given IV

Intervention Type DRUG

pharmacological study

Correlative studies

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have given written, personally signed and dated, informed consent to participate in the study before initiating any study related procedures
* Body mass index (BMI) at least 17 calculated as weight in kg/height in m\^2
* Must have histopathologically/cytologically confirmed primary tumors for which docetaxel is an appropriate or reasonable treatment option
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
* Must have recovered from any toxic effects of previous chemotherapy or radiotherapy as judged by the investigator to =\< grade 1
* Previous chemotherapy/radiotherapy/targeted therapy should have been completed at least 4 weeks prior to start of NDLS administration
* Life expectancy of at least 6 months
* Female patients of child bearing potential must have negative serum pregnancy test at screening
* Sexually active women, unless surgically sterile (at least 6 months prior to study drug administration) or postmenopausal for at least 12 consecutive months, must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives \[any hormonal method in conjunction with a secondary method\], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile \[at least 6 months prior to study drug administration\] sexual partner) for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug; cessation of birth control after this point should be discussed with a responsible physician
* In case of male patients: either patient partners or patients themselves must use an effective method of avoiding pregnancy for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug or till next chemotherapy cycle
* Absolute neutrophil count (ANC) \>= 1500/mm\^3
* Platelet count \>= 100,000/mm\^3
* Hemoglobin \>= 9 gm/dl
* Serum creatinine \< 1.5 times upper limit of normal (ULN)
* Total bilirubin =\< ULN
* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \< 2.5X ULN if alkaline phosphatase \< 2.5 ULN
* AST/ALT \< 1.5 X ULN if alkaline phosphatase \> 2.5 ULN
* Alkaline phosphatase must be \< 5 x ULN on all cases

Exclusion Criteria

* Hypersensitivity to docetaxel injection or any of its excipients
* Intolerance to any antineoplastic agents belonging to the taxane family
* Prior anticancer therapy within 28 days prior to the first day of study treatment
* Participation in another experimental drug study within 30 days prior signing the informed consent form (ICF)
* Any of the following cardiac conditions:

* Unstable angina
* Myocardial infarction within the past 6 months
* New York State Heart Association (NYHA) class II-IV heart failure
* Uncontrolled angina
* Severe uncontrolled ventricular arrhythmias
* Clinically significant pericardial disease
* Electrocardiographic evidence of acute ischemic or active conduction system abnormalities
* Evidence of abnormal cardiac conduction (e.g., bundle branch block or heart block) are eligible if their disease has been stable for the past six months \* History of cardiac disease that met the NYHA classification class 2 or greater
* Use of any recreational drugs or history of drug addiction
* Known history of brain metastasis
* Pre-existing motor or sensory neurotoxicity of a severity \>= grade 2 by National Cancer Institute (NCI) criteria
* Positive hepatitis screening (hepatitis screen includes hepatitis B surface antigen \[HBsAg\], hepatitis C virus \[HCV\] and hepatitis A virus \[HAV\] \[immunoglobulin M (IgM)\] antibody)
* Known case of active infection including human immunodeficiency virus (HIV) infections
* Any other condition that, in the investigator's judgment, might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study
* Abnormal baseline findings considered by the investigator to indicate conditions that might affect study endpoints
* Donation of blood (1 unit or 350 mL) within 90 days prior to receiving the first dose of study medicine
* Known, existing uncontrolled coagulopathy

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No